ZBH.SW Zimmer Biomet (SIX) down 13.50% pre-market 13 Jan 2026: what to watch
Pre-market trading shows ZBH.SW stock sliding -13.50% to CHF70.50 on 13 Jan 2026 after a sharp gap down from CHF81.50. We note a one-day drop of CHF11.00 on very light volume (19.00 shares). The move puts Zimmer Biomet below its 50-day average of CHF81.36 and 200-day average of CHF90.42 on the SIX Swiss exchange, prompting renewed focus on fundamentals, technicals, and Meyka AI model forecasts.
ZBH.SW stock: Pre-market price action
Zimmer Biomet (ZBH.SW) opened pre-market at CHF70.50, down -13.50% from the previous close. The tiny reported volume of 19.00 suggests the move was driven by block orders or cross-listed flows rather than broad retail selling. Year high remains CHF119.00 and year low now equals today’s price at CHF70.50, highlighting recent volatility and a large retracement from 2025 highs.
Earnings, valuation and fundamentals
Latest company metrics show EPS CHF3.18 and a trailing PE of 22.17. Zimmer Biomet’s market cap on SIX is about CHF13,971,799,628.00, with revenue per share CHF38.38 and book value per share CHF51.33. Operating cash flow per share is CHF8.08, free cash flow per share is CHF6.44, and the current ratio is 2.43, supporting near-term liquidity.
Technical snapshot and sector context
Technicals are oversold: RSI 18.81 and CCI -266.00 signal short-term exhaustion while ADX 53.75 shows a strong trend. Price sits below the 50-day (CHF81.36) and 200-day (CHF90.42) averages. Healthcare sector peers trade at an average PE of 33.47, so ZBH.SW’s PE of 22.17 is below sector valuation, suggesting relatively cheaper multiples amid sector strength (+7.74% one month).
Meyka AI rates ZBH.SW with a score out of 100
Meyka AI rates ZBH.SW with a score out of 100: 65.73 / 100, Grade B, Suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector and industry comparison, financial growth, key metrics, forecasts, analyst consensus, and fundamental growth. These grades are not guaranteed and we are not financial advisors.
Meyka AI forecast and price targets
Meyka AI’s forecast model projects a quarterly price of CHF76.29 and a 12-month price of CHF63.22. The quarterly target implies an upside of +8.21% from today’s CHF70.50, while the 12-month target implies a downside of -10.33%. Forecasts are model-based projections and not guarantees; they reflect mean-path scenarios from historical drivers and sector trends.
Risks, opportunities and trading implications
Downside catalysts include weaker near-term surgical volumes and margin pressure from inventory and supply-chain dynamics. Upside drivers include product mix recovery, cost control, and stronger reimbursement in key markets. For pre-market traders, the low volume suggests caution; institutional or cross-border flows likely amplified the move. Consider position-sizing and limit orders while waiting for normal market volume.
Final Thoughts
Key takeaways: ZBH.SW stock fell -13.50% pre-market to CHF70.50 on 13 Jan 2026, putting the share price below both the 50-day and 200-day averages. Fundamentals remain mixed: trailing PE 22.17, EPS CHF3.18, and positive operating cash flow per share CHF8.08. Meyka AI’s model projects a short-term level of CHF76.29 (+8.21%) and a 12-month level of CHF63.22 (-10.33%), signaling divergent near-term and medium-term scenarios. Our proprietary grade, 65.73/100 (B, HOLD), balances valuation support with execution and demand risk. Traders should watch volume recovery, upcoming earnings on 5 Feb 2026, and sector momentum before increasing exposure. Meyka AI, our AI-powered market analysis platform, flags oversold technicals but advises disciplined risk controls and confirmation before trade entries. Forecasts are model-based projections and not guarantees.
FAQs
Why did ZBH.SW stock drop so sharply pre-market?
The pre-market drop to CHF70.50 likely reflects low-volume cross-listed flows, a block trade, and profit-taking after a long run. No single public analyst update explains the move; watch volume and overnight trade prints for confirmation.
What are the near-term price targets for ZBH.SW stock?
Meyka AI projects a quarter target of CHF76.29 and a 12-month target of CHF63.22. The model implies near-term upside of +8.21% and 12-month downside of -10.33%. Forecasts are projections, not guarantees.
How does Zimmer Biomet’s valuation compare to its sector?
Zimmer Biomet trades at PE 22.17, below the Healthcare sector average PE 33.47. That gap suggests a cheaper multiple versus peers, but margin and growth differentials explain part of the discount.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
